Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Victrex plc is a British-based manufacturer and supplier of high-performance polymers, specializing in PEEK and PAEK-based materials. Established in 1993 through a management buyout and listed on the London Stock Exchange since 1995, the company is headquartered in Thornton Cleveleys, Lancashire, with global operations serving over 40 countries and more than 1,100 employees. Victrex plc leads in innovative polymer solutions for demanding applications, producing products like VICTREX PEEK polymer, pipes, films, and coatings under brands such as VICOTE and APTIV. Its business divides into Victrex Polymer Solutions for industrial uses and Invibio Biomaterial Solutions for medical implants. The company impacts key sectors including aerospace (over 20,000 aircraft), automotive (500 million+ applications), electronics (4 billion+ smartphones), energy (75 million+ seal rings), general industrial (100 million+ machines), and medical (15 million+ implanted devices). With 40 years of experience pioneering sustainable, high-performance thermoplastics, Victrex plc invests 6% of sales in R&D, aligning with megatrends like climate change and technological advancement to address material challenges worldwide.
£5.90
+£0.02 (+0.34%)
EOD Jul 3, 2026
13.43% operating margin is respectable but not wide. ROIC at 5.91%. Suggests the business covers its cost of capital, but doesn't point to a wide moat.
Revenue growth slowed to 0.1%, essentially flat. Margins also contracted 2.0pp. This is a business that needs a catalyst.
Even for strong businesses, today's 19x P/E means the stock needs to keep delivering. There's no margin of safety if growth disappoints.
18.6x earnings, 10.4x FCF. Valuation is in a reasonable range. The main question is whether the business can re-accelerate or if current trajectory is already priced in.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
£296M
Net Income (TTM)
£25M
▲ +57.6% YoY
Op. Margin
13.43%
▼ -2.0pp YoY
ROIC
5.91%
Cash Flow & Balance Sheet
FCF (TTM)
£49M
▼ -4.1% YoY
Op. Cash Flow (TTM)
£71M
▼ -15.4% YoY
Net Debt
£25M
Cash & Equiv.
£24M
3Y CAGR: -4.6%
3Y CAGR: +12.6%
Continue Research
At a P/E of 18.6 and a price-to-free-cash-flow of 10.4, Victrex (VCT.XLON) trades below a two-stage DCF intrinsic value of about £9.53 per share, so at £5.90 the stock looks undervalued (61.6% below estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Victrex scores 50/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. It currently yields about 10.1%; see dividend safety for coverage and history. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about £9.53 per share for VCT.XLON, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around £7.15. At today's £5.90, that puts the stock about 61.6% below estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Victrex scores 50 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a 13.4% operating margin and a 5.9% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Yes, Victrex pays a regular dividend of about £0.60 per share per year (typically in quarterly installments), a yield of roughly 10.1% at the current price. That is a payout ratio of about 208.0% of earnings, so the dividend is stretched at this level. A low headline yield is not the same as a weak dividend: what matters is how well earnings and free cash flow cover the payout and whether it is growing, not the percentage alone. For VCT.XLON's full payout history, growth streak and dividend-safety score, see the dividends tab.
That depends on valuation and quality together, not either alone. VCT.XLON currently trades below its estimated intrinsic value and scores 50/100 on quality (mixed). It also yields about 10.1%. A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.